TAS4464

• CAT Number: I018984
• CAS Number: 1848959-10-3
• Molecular Formula: C₂₁H₂₃FN₆O₆S
• Molecular Weight: 506.51
• Purity: ≥95%
• Target: NEDD8-activating Enzyme
• IUPAC Name: 4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]oxolan-2-yl]-5-[2-(2-ethoxy-6-fluorophenyl)ethynyl]pyrrolo[2,3-d]pyrimidine
• InChI: InChI=1S/C21H23FN6O6S/c1-2-33-14-5-3-4-13(22)12(14)7-6-11-9-28(20-16(11)19(23)25-10-26-20)21-18(30)17(29)15(34-21)8-27-35(24,31)32/h3-5,9-10,15,17-18,21,27,29-30H,2,8H2,1H3,(H2,23,25,26)(H2,24,31,32)/t15-,17-,18-,21-/m1/s1
• InChIKey: TZTRUHFXPVXWRD-QTQZEZTPSA-N
• SMILES: CCOC1=C(C(=CC=C1)F)C#CC2=CN(C3=NC=NC(=C23)N)[C@H]4[C@@H]([C@@H]([C@H](O4)CNS(=O)(=O)N)O)O

TAS4464（Cat No.:I018984）is an investigational small-molecule drug designed as a selective inhibitor of the protein tyrosine phosphatase 1B (PTP1B). PTP1B is involved in regulating insulin signaling, and its inhibition may enhance insulin sensitivity, making TAS4464 a potential therapeutic candidate for type 2 diabetes and other metabolic disorders. Additionally, PTP1B inhibition has been linked to improving glucose metabolism and reducing inflammation. TAS4464 is currently undergoing preclinical and clinical studies to evaluate its safety, efficacy, and potential to address insulin resistance and other conditions related to metabolic dysfunction.

Reference

[1]. Yoshimura C, et al. TAS4464, a highly potent and selective inhibitor of NEDD8 activating enzyme, suppresses neddylation and shows antitumor activity in diverse cancer models. Mol Cancer Ther. 2019 May 15.